300298 Sinocare Inc.
- 27.82
- +0.70+2.58%
Sinocare Inc. News
Sinocare Inc.'s (SZSE:300298) Share Price Not Quite Adding Up
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 32x, you may consider Sinocare Inc. (SZSE:300298) as a stock to potentially avoid with its 43x P/E ratio. No
Sannuo Biotech (300298.SZ) has repurchased a total of 3.4215 million shares at a cost of 84.9729 million yuan
Sannuo Biotech (300298.SZ) announced that as of April 30, 2024, the company has passed a share repurchase exclusive...
Sinocare Inc.'s (SZSE:300298) Most Bullish Insider Is CEO Shao Bo Li, and Their Holdings Value Went up by 16% Last Week
Key Insights Significant insider control over Sinocare implies vested interests in company growth The top 3 shareholders own 59% of the company Institutional ownership in Sinocare is 25% Every i
Sannuo Biotech (300298.SZ) announced first-quarter results, net profit of 809.376 million yuan, an increase of 35.51% over the previous year
According to Zhitong Finance App, Sannuo Biotech (300298.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 1,014 billion yuan, an increase of 14.92%; net profit attributable to shareholders of listed companies was 809.376 million yuan, an increase of 35.51% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 77.5811 million yuan, an increase of 21.48% year on year; basic earnings per share were 0.1,457 yuan.
Sinocare's (SZSE:300298) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Sinocare Inc. (SZSE:300298) shareholders might understandably be very concerned that the share price has dropped 32% in the last quarter. But that doesn't change the fact that the returns over the
Sannuo Biotech (300298.SZ) has spent 84.97 million yuan to buy back 3.4215 million shares
According to Zhitong Finance App, Sannuo Biotech (300298.SZ) announced that as of March 31, 2024, the company had repurchased a total of 3.4215 million shares of the company's shares through a special stock repurchase account, accounting for 0.61% of the company's total share capital. The highest transaction price was 26.75 yuan/share, the minimum transaction price was 23.80 yuan/share, and the total transaction amount was 84.97 million yuan.
We Think Sinocare (SZSE:300298) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Calculating The Fair Value Of Sinocare Inc. (SZSE:300298)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Sinocare fair value estimate is CN¥25.69 Current share price of CN¥21.99 suggests Sinocare is potentially trading close to its fair value O
Sannuo Biotech (300298.SZ): Repurchase 0.61% of shares at a cumulative cost of 84.97.29 million yuan
Gelonghui, March 5, 丨 Sannuo Biotech (300298.SZ) announced that as of February 29, 2024, the company had repurchased 3,421,500 shares of the company's shares through a special stock repurchase account, accounting for 0.61% of the company's total share capital of 564,265,373 shares. The highest transaction price was 26.75 yuan/share, the minimum transaction price was 23.80 yuan/share, and the total transaction amount was 84.97.29 million yuan (excluding transaction fees).
Changes in Hong Kong stocks | Ping An Good Doctor (01833) rose nearly 5% in the afternoon. The company reached deep strategic cooperation with Sannuo Biotech and Umile
Dr. Ping An (01833) rose nearly 5% in the afternoon. As of press release, it rose 3.78% to HK$12.62, with a turnover of HK$458.24,500.
Is Sinocare Inc.'s (SZSE:300298) Stock On A Downtrend As A Result Of Its Poor Financials?
With its stock down 18% over the past month, it is easy to disregard Sinocare (SZSE:300298). Given that stock prices are usually driven by a company's fundamentals over the long term, which in this
Sannuo Biotech (300298.SZ): Controlling shareholder Li Shaobo lifted 5 million shares pledge
Gelonghui, Feb. 6, 丨 Sannuo Biotech (300298.SZ) announced that the company recently received a notice from Mr. Li Shaobo, the controlling shareholder and actual controller of the company, and learned that some of the company's shares held by the company have been cancelled. 5 million shares have now been released from pledge.
Sinocare Inc.'s (SZSE:300298) 29% Share Price Plunge Could Signal Some Risk
The Sinocare Inc. (SZSE:300298) share price has fared very poorly over the last month, falling by a substantial 29%. Instead of being rewarded, shareholders who have already held through the last t
Sannuo Biology (300298.SZ): Recently received a government subsidy of 20.641,300 yuan
On February 5, Gelonghui Biotech (300298.SZ) announced that the company recently received government subsidies for value-added tax rebates for software products, totaling RMB 20.6413 million, accounting for 4.79% of the company's latest audited net profit attributable to shareholders of listed companies.
Sannuo Biotech (300298.SZ) has spent about 84.97 million yuan to buy back 3.4215 million shares
Sannuo Biotech (300298.SZ) issued an announcement. As of January 31, 2024, the company approved shares...
Returns On Capital At Sinocare (SZSE:300298) Have Stalled
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Amongst other things, we'll want to see two things; firstly, a gr
Sannuo Biotech (300298.SZ): 2023 net profit pre-reduced by 25% to 40%
Gelonghui, January 26, 丨 Sannuo Biotech (300298.SZ) announced its 2023 annual performance forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 26,79492 million yuan to 33,936,500 yuan, down 25% to 40% from the same period last year; net profit profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 262,9492 million yuan to 33,393.65 million yuan, down 5.10% to 25.27% from the same period last year. The main reasons for the expected year-on-year decline in the company's net profit attributable to shareholders of listed companies in 2023 are as follows: 1.
Sannuo Biotech (300298.SZ): Sale of shares of the first phase of the employee stock ownership plan has been completed
Gelonghui, January 17, 丨 Sannuo Biotech (300298.SZ) announced that all of the company's shares held in the first phase of the company's employee stock ownership plan have been sold in batches through centralized bidding transactions in the secondary market from July 22, 2018 to January 15, 2024. The number of shares sold was 12,261,322 shares, accounting for about 2.17% of the company's total share capital.
Sinocare Inc. (SZSE:300298) CEO Shao Bo Li's Holdings Dropped 3.1% in Value as a Result of the Recent Pullback
Key Insights Sinocare's significant insider ownership suggests inherent interests in company's expansion A total of 3 investors have a majority stake in the company with 59% ownership 24% of Sino
Sannuo Biotech (300298.SZ): The total funding limit for the proposed third phase of the employee stock ownership plan is 77.07 million yuan
Gelonghui, January 3, 丨 Sannuo Biotech (300298.SZ) announced the third phase of the employee stock ownership plan (draft). The total number of shares transferred by the employee stock ownership plan is no more than 3 million shares, accounting for 0.54% of the company's total share capital (excluding shares already repurchased by the company). The price of shares to be repurchased by the transferee company is 25.69 yuan/share, which is not lower than the average price of the company to repurchase shares (24.09 yuan/share) and the capital cost of the company's share repurchase (calculated from the company's average financing cost of 3.7% during the repurchase period of July 15, 2021 to July 14, 2022) Measured January 31, 2024
Analysis
Price Target
No Data
